#immunotherapy — Sunday, October 25, 2026 (3 items)
| 13 | ℹ |
Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1-Negative Advanced NSCLC.
(nejm.org)
|
New England Journal of Medicine 2026-10-25 | #clinical trial #immunotherapy #nsclc #oncology #checkpoint inhibitor | |
| 13 | ℹ |
Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC.
(nejm.org)
|
New England Journal of Medicine 2026-10-25 | #clinical trial #nsclc #oncology #mutation #immunotherapy | |
| 8 | ℹ |
ctDNA clearance and outcomes for resectable lung cancer from NeoCOAST-2.
(nature.com)
|
Nature 2026-10-25 | #ctdna #neoadjuvant #immunotherapy #nsclc #biomarker |